In vitro and in vivo trypanocidal activity of some benzimidazole derivatives against two strains of Trypanosoma cruzi

Díaz-Chiguer, Dylan L.; Márquez-Navarro, Adrián; Nogueda‐Torres, Benjamín; León-Ávila, Gloria; Pérez‐Villanueva, Jaime; Hernández‐Campos, Alicia; Castillo, Rafael; Ambrosio, Javier R.; Nieto-Meneses, Rocío; Yépez‐Mulia, Lilián; Hernández‐Luis, Francisco

doi:10.1016/j.actatropica.2011.12.009

Cited by 35 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Benznidazole treatment, at 10 mg/kg and 100 mg/kg, show a pronounced decrease in parasitemia, consistent with other reports in the literature (Díaz-Chiguera et al, 2012) (Fig. 1).…”

Section: Auranofin Reduced Trypanosoma Cruzi Mice Mortalitysupporting

confidence: 92%

In vivo and in vitro auranofin activity against Trypanosoma cruzi: Possible new uses for an old drug

Silva

Portapilla

et al. 2016

Experimental Parasitology

View full text Add to dashboard Cite

“…Benznidazole treatment, at 10 mg/kg and 100 mg/kg, show a pronounced decrease in parasitemia, consistent with other reports in the literature (Díaz-Chiguera et al, 2012) (Fig. 1).…”

Section: Auranofin Reduced Trypanosoma Cruzi Mice Mortalitysupporting

confidence: 92%

In vivo and in vitro auranofin activity against Trypanosoma cruzi: Possible new uses for an old drug

Silva

Portapilla

et al. 2016

Experimental Parasitology

View full text Add to dashboard Cite

“…Compounds isolated were tested in bioassays against the human breast cancer cell line MCF-7 100 , the malaria parasite ( Plasmodium falciparum ) 101, 102 and the Chagas’ disease causative agent ( Trypanosoma cruzi ) 100, 103, 104 , Escovopsis ACRO424 and TZ49, Aspergillus fumigatus (ATCC® 1028™) 105 , Candida albicans (ATCC® 10231™), Staphylococcus aureus subsp. aureus (ATCC® 43300™) and Bacillus subtilis subsp.…”

Section: Methodsmentioning

confidence: 99%

Imaging mass spectrometry and MS/MS molecular networking reveals chemical interactions among cuticular bacteria and pathogenic fungi associated with fungus-growing ants

Fernández‐Marín

Mejía

et al. 2017

Sci Rep

View full text Add to dashboard Cite

The fungus-growing ant-microbe symbiosis is an ideal system to study chemistry-based microbial interactions due to the wealth of microbial interactions described, and the lack of information on the molecules involved therein. In this study, we employed a combination of MALDI imaging mass spectrometry (MALDI-IMS) and MS/MS molecular networking to study chemistry-based microbial interactions in this system. MALDI IMS was used to visualize the distribution of antimicrobials at the inhibition zone between bacteria associated to the ant Acromyrmex echinatior and the fungal pathogen Escovopsis sp. MS/MS molecular networking was used for the dereplication of compounds found at the inhibition zones. We identified the antibiotics actinomycins D, X2 and X0β, produced by the bacterium Streptomyces CBR38; and the macrolides elaiophylin, efomycin A and efomycin G, produced by the bacterium Streptomyces CBR53.These metabolites were found at the inhibition zones using MALDI IMS and were identified using MS/MS molecular networking. Additionally, three shearinines D, F, and J produced by the fungal pathogen Escovopsis TZ49 were detected. This is the first report of elaiophylins, actinomycin X0β and shearinines in the fungus-growing ant symbiotic system. These results suggest a secondary prophylactic use of these antibiotics by A. echinatior because of their permanent production by the bacteria.

show abstract

“…Despite a large reduction of new acute cases in recent years due to vectorial transmission control policies, other routes of infection, including vertical transmission (mother to fetus) and ingestion of contaminated food and drinks (1), are still a concern. T. cruzi is restricted to Latin America, where about 10 million people are infected and 25 to 90 million are at risk of acquiring the infection (2). According to the Pan American Health Organization (PAHO) and the World Health Organization (WHO), CD causes between 10,000 and 14,000 deaths per year (3).…”

mentioning

confidence: 99%

Activities of Psilostachyin A and Cynaropicrin against Trypanosoma cruzi In Vitro and In Vivo

Silva

Batista

Araújo

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

In vitro and in vivo activities against Trypanosoma cruzi were evaluated for two sesquiterpene lactones: psilostachyin A and cynaropicrin. Cynaropicrin had previously been shown to potently inhibit African trypanosomes in vivo, and psilostachyin A had been reported to show in vivo effects against T. cruzi, albeit in another test design. In vitro data showed that cynaropicrin was more effective than psilostachyin A. Ultrastructural alterations induced by cynaropicrin included shedding events, detachment of large portions of the plasma membrane, and vesicular bodies and large vacuoles containing membranous structures, suggestive of parasite autophagy. Acute toxicity studies showed that one of two mice died at a cynaropicrin dose of 400 mg/kg of body weight given intraperitoneally (i.p.). Although no major plasma biochemical alterations could be detected, histopathology demonstrated that the liver was the most affected organ in cynaropicrin-treated animals. Although cynaropicrin was as effective as benznidazole against trypomastigotes in vitro, the treatment (once or twice a day) of T. cruzi-infected mice (up to 50 mg/kg/day cynaropicrin) did not suppress parasitemia or protect against mortality induced by the Y and Colombiana strains. Psilostachyin A (0.5 to 50 mg/kg/day given once a day) was not effective in the acute model of T. cruzi infection (Y strain), reaching 100% animal mortality. Our data demonstrate that although it is very promising against African trypanosomes, cynaropicrin does not show efficacy compared to benznidazole in acute mouse models of T. cruzi infection.A merican trypanosomiasis, also known as Chagas disease (CD), is a neglected disease caused by the intracellular protozoan Trypanosoma cruzi. Despite a large reduction of new acute cases in recent years due to vectorial transmission control policies, other routes of infection, including vertical transmission (mother to fetus) and ingestion of contaminated food and drinks (1), are still a concern. T. cruzi is restricted to Latin America, where about 10 million people are infected and 25 to 90 million are at risk of acquiring the infection (2). According to the Pan American Health Organization (PAHO) and the World Health Organization (WHO), CD causes between 10,000 and 14,000 deaths per year (3). Currently, only two drugs, benznidazole (Bz) and nifurtimox, are available for chagasic patients (4). However, the poor tolerance to and limited efficacy of these drugs, especially in the later stage of the chronic phase, make the search for novel compounds and therapeutic strategies ever more important as a means to offer alternative therapies to patients refractory to both these nitro derivatives (5).Natural products are an excellent source of active compounds. In fact, despite them comprising Ͻ1 percent of known chemical compounds (DNP 2013 [http://dnp.chemnetbase.com/tour/]; Reaxys 2013 [https://www.reaxys.com/documentation/about _query.htm]), they have supplied or inspired more than half of all new drugs introduced to the market in the last 3 dec...

show abstract

In vitro and in vivo trypanocidal activity of some benzimidazole derivatives against two strains of Trypanosoma cruzi

Cited by 35 publications

References 24 publications

In vivo and in vitro auranofin activity against Trypanosoma cruzi: Possible new uses for an old drug

In vivo and in vitro auranofin activity against Trypanosoma cruzi: Possible new uses for an old drug

Imaging mass spectrometry and MS/MS molecular networking reveals chemical interactions among cuticular bacteria and pathogenic fungi associated with fungus-growing ants

Activities of Psilostachyin A and Cynaropicrin against Trypanosoma cruzi In Vitro and In Vivo

Contact Info

Product

Resources

About